Literature DB >> 12058090

Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study.

L A Pfeifer1, L R White, G W Ross, H Petrovitch, L J Launer.   

Abstract

OBJECTIVE: To investigate the relationship between cerebral amyloid angiopathy (CAA), dementia, and cognitive function in an autopsy sample of 211 Japanese-American men from the population-based Honolulu-Asia Aging Study.
METHODS: Starting in 1991, participants were assessed with the Cognitive Abilities Screening Instrument (CASI) and diagnosed with dementia (including subtype) based on published criteria. At autopsy, neuropathologists blinded to clinical data examined brains for neurofibrillary tangles (NFT), neuritic plaques (NP), and a number of vascular pathologies, including CAA. CAA was detected by immunostaining for betaA4 amyloid in parenchymal vessels in the neocortex and semiquantitatively rated. Linear regression models were used to examine the association of CASI score, dementia subtype, and CAA controlling for age at death, time between CASI administration and death, education, NP and NFT counts, infarcts, hemorrhage, and APOE genotype.
RESULTS: A total of 44.1% of subjects had CAA in at least one neocortical area. The presence of CAA was associated with higher mean NFT and NP counts and having at least one APOE-epsilon4 allele. The interaction between CAA and AD on the adjusted mean CASI score was significant; compared with nondemented men without CAA, the CASI score was 16.6% lower in men with AD and no CAA and 45.9% lower in men with AD plus CAA.
CONCLUSIONS: CAA may contribute to the clinical presentation of dementia by interacting with other neuronal pathologies, leading to more severe cognitive impairment in men with both CAA and AD compared with men with only AD or CAA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12058090     DOI: 10.1212/wnl.58.11.1629

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  107 in total

1.  Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease.

Authors:  J Tian; J Shi; K Bailey; C L Lendon; S M Pickering-Brown; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 2.  Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke.

Authors:  Rebecca F Gottesman; Argye E Hillis
Journal:  Lancet Neurol       Date:  2010-09       Impact factor: 44.182

3.  Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma.

Authors:  Alberto Broniscer; Justin N Baker; Suzanne J Baker; Susan N Chi; J Russell Geyer; E Brannon Morris; Amar Gajjar
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

4.  Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology.

Authors:  Jason Hassenstab; Sarah E Monsell; Charles Mock; Catherine M Roe; Nigel J Cairns; John C Morris; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

5.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

6.  Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers.

Authors:  Hyemin Jang; Young Kyoung Jang; Hee Jin Kim; David John Werring; Jin San Lee; Yeong Sim Choe; Seongbeom Park; Juyeon Lee; Ko Woon Kim; Yeshin Kim; Soo Hyun Cho; Si Eun Kim; Seung Joo Kim; Andreas Charidimou; Duk L Na; Sang Won Seo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

Review 7.  Alzheimer's silent partner: cerebral amyloid angiopathy.

Authors:  Tanya L Cupino; Matthew K Zabel
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

8.  Impaired visual evoked flow velocity response in cerebral amyloid angiopathy.

Authors:  E E Smith; M Vijayappa; F Lima; P Delgado; L Wendell; J Rosand; S M Greenberg
Journal:  Neurology       Date:  2008-10-28       Impact factor: 9.910

Review 9.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 10.  Vascular Cognitive Impairment.

Authors:  Jonathan Graff-Radford
Journal:  Continuum (Minneap Minn)       Date:  2019-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.